BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-27@catalystbrief.girapphe.com
DTSTAMP:20261117T061547Z
LAST-MODIFIED:20261117T061547Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Guangdong Hengrui Pharmaceutical Co.\, Ltd — SHR-1819 In
 jection [Dec 2026]
DESCRIPTION:Phase 3 primary completion: A Clinical Study Evaluating the Eff
 icacy and Safety of SHR-1819 Injection in Patients With Seasonal Allergic 
 Rhinitis.\nSource: https://clinicaltrials.gov/study/NCT07688772\nhttps://c
 atalystbrief.girapphe.com/e/27?lang=en\nNot investment advice. Dates may c
 hange.
URL:https://catalystbrief.girapphe.com/e/27?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
